332370-57-7

Upstream product

• 610-35-5 4-hydroxyphthalic acid 
• 1493-27-2 ortho-nitrofluorobenzene 
• 22479-95-4 dimethyl 4-hydroxyphthalate 
• 332370-51-1 4-(2-nitrophenoxy)phthalic acid dimethyl ester 

Downstream Products

• 332368-89-5 4-[2-(3-nitrobenzoylamino)-phenoxy]phthalic acid dimethyl ester 
• 332369-80-9 4-(2-benzoylaminophenoxy)phthalic acid dimethyl ester 
• 332369-75-2 4-[2-(3-chlorobenzoylamino)phenoxy]phthalic acid dimethyl ester 
• 332369-02-5 4-[2-(3-ethoxycarbonylbenzoylamino)phenoxy]phthalic acid dimethyl ester 

Relevant academic research and scientific papers

Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site

Inhibition of glycogen phosphorylase (GP) has attracted considerable attention during the last five to 10 years as a means of treating the elevated hepatic glucose production seen in patients with type 2 diabetes. Several different GP inhibitors binding t

A new class of glycogen phosphorylase inhibitors

A new class of diacid analogues that binds at the AMP site not only are very potent but have ～10-fold selectivity in liver versus muscle glycogen phosphorylase (GP) in the in vitro assay. The synthesis, structure, and in vitro and in vivo biological evaluation of these liver selective glycogen phosphorylase inhibitors are discussed.

Aromatic compounds

Disclosed are compounds of formula I wherein A, R1, R2, R3, R4and R5are described in the specification, pharmaceutical formulations comprising these compounds, the use of these compounds are medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes), as well as methods for treating diabetes comprising administration of these compounds.